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ABSTRACT
Aim: Toexploretheattitudes, perceptions andconcernsamong
decision makers about equity of access to high-cost drugs in
public hospitals.
Method: 25in-depth. semi-structured interviews wereconducted
with seniorhospitaladministrators, directors of pharmacy and
senior medical doctors. Topics included the decision-making
process andassociated problems, andsolutions to issues ofaccess
to high-cost drugs. Interviews were audiotaped, transcribed
verbatimand thematically analysed.
Results: Healthcare funding models wereperceived asobstacles
to equity of access to high-cost drugs. Participants were
concerned that there were inequities in decisions for individual
patients according to public or private sector status. Tertiary
public hospitals were seen to be at the 'cutting edge' and
therefore were required to fund new and expensive drugs. This
meant prioritising between patient groups and individuals.
Participants had difficulty in identifying solutions. They
suggested thatethical principlesshould be considered in addition
to safety, efficacy and cost. Most wanted a transparent,
accountable, evidence-based decision-making process.
Conclusion: Decision makers were concemed about equity of
access to high-cost drugs in public hospitals. They were also
concerned about processes for decision making and the
outcomes of these decisions.
J Pharm Pract Res 2005; I: 18-20.
INTRODUCTION
Australians have access to medicines through different
schemes. The Pharmaceutical Benefits Scheme (PBS),
funded by the federal government, subsidises drugs
prescribed in the community.' Private hospitals, as well
as some public hospitals, have implemented the PBS as a
•funding mechanism for outpatient and discharge drugs.'
Pharmaceuticals supplied by public hospitals are funded
primarily by the state-based hospital funding.' Thc
clinical status of an inpatient differs from non-hospitalised
patients-the illness is likely to be 1110re acute and other
issues can affect access to medicines."
Funding for public hospitals is given to the states
and territories by the federal government and this
represents the largest single component of health
expenditure.' Pharmaceuticals represent one of the
highest costs within this category.'
How do hospitals deal with capped budgets and
scarce resources? Multidisciplinary drug and therapeutics
committees (DTCs) address cost priorities and aim to ensure
quality use of medicines." Analysis of drug use suggests
that DTCs have become more involved in cost containment
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and predicting budgetary needs." However, the decision-
making process is a complex task and there are frequent
additions of innovative, high-cost drugs. Economic, ethical
and legal aspects may be considered, as well as the clinical
and science-based evidence for drug use.! Expending
resources for the benefit of some patients by depriving
others is challenged as unethical.v'" The appropriate
decision-making process is described as transparent,
allowing fair allocation of resources to achieve the greatest
benefit for patients." High-cost drugs, which may be
defined through a number of mechanisms, may also be
associated with low levels of evidence for the specified
indication, and are often for 'off-label' use.'! Recognition
of these issues does not easily translate to day-to-day
management of drug access issues for individuals,
institutions and policy makers.
Decisions are not based on financial cost alone, as
social, legal and ethical aspects may play significant roles.
Published reports have focused on different mechanisms
of rationing and principles such as distributive justice.'!'!'
Limited work has been conducted regarding use and
funding of high-cost drugs in public hospitals. There are
no published data on attitudes and concerns regarding
access to high-cost drugs.
The aim of this study was to explore the attitudes,
perceptions and concerns among decision makers about
equity of access to high-cost drugs in public hospitals.
This study is part of a larger research program
investigating attitudes, perceptions and concerns of the
community. Our specific objectives were to:
investigate the understanding of decision makers
about high-cost drugs;
investigate their perceptions, concerns and attitudes
regarding the use of high-cost drugs;
investigate current problems and possible solutions;
investigate the criteria currently used to allocate
resources to high-cost drugs; and
explore the role of economic evaluation (and other
data) in the decision-making process.
METHOD
Qualitative techniques were used for data collection and
analysis. In-depth, semi-structured interviews were
conducted between August 2003 and April 2004. All
interviews were conducted by the same researcher and
were of about 35 minutes duration.
A purposive sample of key decision makers within
the Sydney Area Health Service was identified. This
included senior hospital administrators, directors of
phannacy and senior medical doctors. A letter of invitation
which outlined the objectives of the study was sent and
a reminder letter was sent if no response W3S obtained
within four weeks. A 'patient information' statement and
a consent form were provided.
Interviews were audiotaped and transcribed verbatim.
When new themcs were no longer occurring data
collection was considered complete. The data were coded
and analysed through the strategies of grounded theory.
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This is a standard technique used to establish a
theoretical framework from collected data.
The characteristics of the participants, including age,
gender, position, organisation and education background
were recorded. Data were analysed using the Statistical
Package for the Social Sciences (version 10).
This study was approved by the Human Research
Ethics Committees of The University of Sydney and St
Vincent's Hospital, Sydney and endorsed by the Chief
Executive Officer of the Sydney Area Health Service.
RESULTS
Thirty-four people were invited to participate (Table I)
and 25 semi-structured interviews were conducted. One
participant declined to be audio taped and another was
interviewed twice to clarify previous answers.













Senior medical doctor 25%
Director of hospital pharmacy 21%






Participants were initially asked to define a high-cost
drug. Most defined these in two ways: drugs with a high
acquisition cost used in low volume or drugs with low
acquisition cost but used in high volume. A minority
attempted to give a dollar value to the definition. They
were ultimately concerned about drugs that had an impact
on the capped and limited budgets. So I think yOIl have
to talk about the two situations, aile being that a drug
that costs a $1000 is given for a short period of time,
and other drugs which cost less than that are given
over larger periods of time. The more common thing
that I worry about is in an individual case. You have
something that is say over $J5 000 per year- that is
the sort of'figure that I start gelling worried about. The
high-cost drugs that we tend to focus 011 are those ill
which the individual doses or courses are expensive
and as a consequence a small variation in the number
of eligible patients makes a large variation in the
hospital s budgetary position.
Associated Problems and Solutions
Participants were asked about what they perceived to be
the main problems and their concerns with regards to
access to high-cost drugs. One of the main themes that
arose was the tension between funding models. They
perceived the current health care funding model as an
obstacle to equity of access to high-cost drugs. But
because it s high cost to us and therefore there s a
question of can we afford to use it and what are its
indications, etc. III the private sector that s a non-
question because it's PBS listed and the Commonwealth
simply pays for it. The anomaly we see and the system
which appears to be lacking at a federal/state interface
level is that the decisions of the federal government are
not binding 011 the state government and hence the
decision that the taxpayer should not pay for this dug is
overturned at hospital level and the same taxpayer pays
for the drug.
Participants were also concerned that there were
inequities in decisions for individual patients according
to public or private sector status. There are issues of
equity of access, particularly with drugs that are
available in the PBS and available to the people in
private hospitals but the public hospital can't make
the same drugs available; there s a lot of issues with
funding. There are issues relating to equity and access
between private hospitals and public hospitals. There
are a number of drugs which are available on the PBS
and in some Cases not available in public hospitals
because they have been deemed too expensive or their
use may be restricted.
Some respondents thought that public hospitals had
to be at the 'cutting edge' and therefore were required to
fund new, expensive drugs. A major concern for
respondents was that, as a consequence, this meant
prioritising between patient groups and individual cases.
So, by and large, teaching hospitals are where new
and expensive therapies are used first to the utmost
degree of good. Why is one patient group more
important than another patient group and how do we
decide which drugs should be available to each
patient?
The majority of participants identified problems but
had difficulty in identifying solutions. Some perceived
that having a single body to fund pharmaceuticals would
overcome the problems. Universal funding of
pharmaceuticals by the Commonwealth. It would be
easier to make it transparent and equitable decisions by
having a single funding body.
Adopting the decision of the Pharmaceutical Benefits
Advisory Committee (PBAC) model was also suggested.
It would simplify matters enormously if the States and
the Commonwealth agreed that a PBAC listing that a
particular drug should not be publicly funded meant
exactly what it said and that there was no debate at
state level or area level or hospital level.
They also commented on having a state-based
approach to dealing with high-cost drugs and the
involvement of advisory bodies. Well if we're still having
separate funding for hospitals, I think some of these
issues should be a state approach because it s not ... it s
inequitable. I think the New South Wales Therapeutic
Assessment Group, although they are not a government
body, they have almost a direct pharmacy [sic] all them
and they have the skills to see whether these drugs,
high-cost drugs, are they, well, worthwhile, and what it
is all about. And make all appropriate recommendation.
Allocating Resources
Participants described criteria such as safety,
effectiveness, efficacy and cost. Although it seemed like
cost was the main criteria used by them it was perceived
unethical to consider it as the sole driver for the decision.
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A utilitarian goal was in mind-'the greatest good for the
greatest number'. Efficacy, safety and cost effectiveness
would have to be included as they are in the PBAC. So
it s total cost that s the most important driver as far as
the hospital relates. Evidence, costing, number of
patients per year, alternatives that have been used to
date and why, why this drug is needed for that person.
Cost isn ~ an appropriate way of rationing the resources.
You can ~ just deal with the costs alone, there has to be
cost versus the clinical benefit. We do apply roughly the
same criteria, philosophical criteria, in the sense that
we try to get the maximum benefit for the greatest number.
Economic Evaluation
Participants were asked if economic evaluation was used
as a criterion to allocate resources to high-cost drugs.
No attempt was made to verify their understanding of
pharmacoeconomics. Pharmacoeconomics is currently
not used as a criterion in the decision-making process in
public hospitals. Interviewees identified three main
barriers to its use:
Lack of expertise and knowledge to analyse the data
derived from pharmacoeconomic studies.
Most pharmacoeconomic studies were sponsored
by pharmaceutical companies.
Most pharmacoeconomic studies are conducted
from the societal perspective, and are available for
PBS subsidy criteria. This perspective differs to that
of public hospitals.
And we don ~ have enough expertise. We'd oversee so
called pharmacoeconomic evaluations and yOli can't
directly relate them to the Australian scenario; it is very,
vefY hard, there are so many issues. It would be nice to
have access to cost-effectiveness analysis done by pro-
fessionals. Doing economic studies as to the reductions
of length of stay and all of those sorts of things. But of
course that is completely useless to a public hospital
point of view.
DISCUSSION
Despite many allusions to cost of health care there are
no generally accepted definitions of high-cost drugs. This
may be important in the interpretation of data and
development of policy.!':" In this study, participants
unanimously defined high-cost drugs as those which
could have an impact on capped and limited budget
holdings. Similar definitions have been previously
described. IS They were principally concerned with those
with a high acquisition cost and a low volume of usage.
Dealing with high-cost drugs was considered diffi-
cult for a number of reasons. These included the complex
healthcnre systems, federal government and state as well
as public and private systems.v':'? A single funding sys-
tem was seen by some as a way to overcome the previ-
ous problems." However, participants achieved no
consensus and other approaches were described.
As expected, cost was described as a major criterion
when deciding if a high-cost drug should be available at
a public hospital. Participants acknowledged that there
was rationing of resources and they had difficulties
describing how this should be achieved. There was a
utilitarian viewpoint expressed where they wanted to
achieve 'greatest good for the greatest number'.
Phermacoeconomic data were not being used in the
decision-making process-lack of expertise and
knowledge were identified as barriers. Similar results were
obtained when exploring the role of economic evaluation
for health services." Biased information and lack of
phannacoeconomic analysis conducted from the hospital's
viewpoint were also identified as barriers to usc.
Qualitative research is not intended to produce results
which can be generalised. It allows the exploration of
people's views." .In this study a description of attitudes,
perceptions and concerns among decision makers about
access to high-cost drugs has been provided.
Limited work has been conducted on the use and
funding of high-cost drugs in public hospitals. It is
important to evaluate how individual perceptions may
influence and assist in the decision-making process.
Understanding the role of these perceptions in decision
making will assist in future management of high-cost drugs.
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